Hurrah for another breakthrough in medicine! A wirelessly controlled, implanted drug-delivery chip made its first successful administrations of a drug for osteoporosis, normally given through an injection daily.
The idea, which was developed by professors Robert Langer and Michael Cima of Massachusetts Institute of Technology, is considered “pharmacy on a chip,” as one can ‘instruct’ it to control drug delivery and even administer multiple drugs. The chips are seen to be beneficial changes to treatment, especially for diseases with strict drug-taking compliance, like cancer and multiple sclerosis.
Development and Testing
The development of the implantable chip was started by the MIT team in the mid-1990s, and they published initial findings in 1999. The concept was revolutionary at the time, proposing a method to deliver medication directly into the body without the need for daily injections or oral medications. This innovation aimed to improve patient compliance and ensure more consistent drug delivery.
Effectiveness of the chips was tested starting January 2011 in Denmark. The study involved seven women with osteoporosis, and the drug administered was teriparatide. In the study, the implants were found to deliver the same dosages as injections, with no other health risks. The results were promising, showing that the chip could maintain the necessary drug levels in the bloodstream, which is crucial for the treatment of osteoporosis.
MicroCHIPS, the company behind the successful tests, plans to create versions of the chip with larger doses and more varied drugs. This could potentially revolutionize the way we treat chronic diseases, offering a more convenient and reliable method of drug delivery. The company envisions a future where patients with conditions such as diabetes, cardiovascular diseases, and chronic pain could benefit from this technology.
Potential Impact and Future Applications
The implications of this technology are vast. For patients with chronic conditions, the ability to receive medication without the need for daily injections or pills could significantly improve their quality of life. For instance, cancer patients undergoing chemotherapy could receive their treatment through these chips, reducing the need for frequent hospital visits and minimizing the side effects associated with traditional drug delivery methods.
Moreover, the chip’s ability to administer multiple drugs opens up new possibilities for combination therapies. Patients with complex conditions often require multiple medications, and managing these can be challenging. The chip could simplify this process, ensuring that each drug is delivered at the right time and in the right dosage.
Another exciting prospect is the potential for remote monitoring and control. Healthcare providers could adjust the dosage or switch medications without the need for invasive procedures. This could be particularly beneficial in managing conditions that require frequent adjustments to treatment plans, such as epilepsy or autoimmune diseases.
The technology also holds promise for global health. In regions with limited access to healthcare, these chips could provide a reliable method of delivering essential medications. This could help in managing diseases like tuberculosis or HIV, where adherence to medication schedules is critical for effective treatment.
The wirelessly controlled, implanted drug-delivery chip represents a significant advancement in medical technology. Developed by professors Robert Langer and Michael Cima of MIT, this “pharmacy on a chip” has the potential to transform the way we treat chronic diseases, improve patient compliance, and enhance the overall quality of healthcare. With ongoing research and development, the future of medicine looks promising, and we can expect to see more innovative solutions like this in the years to come.
via MIT News
Latest Geeky Gadgets Deals
Disclosure: Some of our articles include affiliate links. If you buy something through one of these links, Geeky Gadgets may earn an affiliate commission. Learn about our Disclosure Policy.
